Wiz vs Prisma Cloud for Life Sciences Consulting: A Data Worksheet

List every cloud account or storage bucket your practice uses, then note next to each one: what kind of data it holds, whether it's subject to a client NDA or a regulatory framework like HIPAA, and who outside your firm can currently access it. Most consultancies have never done this exercise, and doing it before evaluating either tool tells you which capabilities you actually need. Treat the worksheet as a living artifact you revisit at every new engagement kickoff, not a one-time exercise you file away and forget once it's built.

Each row of the worksheet should record:

• The cloud account or storage bucket itself, so every place your practice keeps client or research data appears on one page.
• The kind of data it holds, such as de-identified trial data, proprietary lab results, client IP under an NDA, or general project files.
• Any client NDA or regulatory framework attached to that data, including HIPAA where it applies.
• Who outside your firm can currently access it, since that answer usually shows the biggest gaps.
• The tool coverage the account actually needs, which becomes the worksheet's last column.

If most of your accounts hold general project files and de-identified analysis rather than regulated patient data, Wiz's agentless scanning gives you solid visibility without asking your small team to maintain agents on infrastructure nobody has a dedicated DevOps role to manage. Its compliance framework mapping also covers HIPAA where that applies, without requiring you to build the mapping yourself.

If your worksheet turns up accounts holding identifiable clinical trial data, or infrastructure a client's own compliance team specifically requires active monitoring on, Prisma Cloud's runtime defenders give you a stronger answer to that specific requirement, at the cost of needing someone on your team, or a contracted DevOps resource, to maintain them.

A common finding in this kind of worksheet exercise is proprietary research data that was copied into a general-purpose storage bucket for convenience during an analysis project and never cleaned up afterward. Neither tool prevents that human habit, but both will flag an overly permissive bucket once you point them at it, which is often how firms discover the copy exists in the first place.

Add a final column to your worksheet: what tool coverage does this account actually need, given what it holds. Most life sciences consultancies end up with a mixed answer, agentless coverage across most of their accounts and targeted runtime protection on the handful that hold genuinely sensitive trial or patient data. That mixed answer is a reasonable outcome, not an unfinished decision. Taj, MeetMyCTO's AI CTO, can help you sanity-check the worksheet once you've filled it in.

Larger pharmaceutical or biotech clients often have their own vendor security requirements that exceed general HIPAA guidance, sometimes specifying particular controls, audit frequencies, or even preferred tooling categories in a master services agreement. Read that agreement's security exhibit closely before assuming either platform automatically satisfies it, and where it's ambiguous, ask the client's compliance contact directly rather than guessing. A clarifying question early in the relationship is far cheaper than a finding during their own audit of you later.

A common gap shows up at project close: data that was appropriately protected during an active engagement often sits untouched in the same cloud account for months or years after the client relationship ends, with the original access controls slowly drifting as staff turn over. Add a project-closeout step to your worksheet process that either archives, restricts, or deletes that data on a defined schedule, rather than leaving it in whatever state it was in on the last day of the engagement.

Before finalizing your tool choice for a new life sciences engagement, have a short conversation with the client's own compliance officer about what evidence they'll expect to see during or after the project. Their answer sometimes points clearly toward one platform's compliance reporting over the other's, and getting that alignment early avoids reworking your evidence trail midway through an active engagement.